Genprex, Inc. (GNPX) Stock Analysis & Investment Frameworks
Genprex, Inc. (GNPX) stock analysis on Invetso. Review Genprex, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Genprex, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Genprex, Inc. Key Financial Metrics
- Market Cap: $1.69M
- Revenue: $N/A
- ROE: -163.13%
- ROIC: -107.08%
- Dividend Yield: N/A
About Genprex, Inc.
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.
Genprex, Inc. Investment Frameworks
Invetso analyzes Genprex, Inc. (GNPX) across the following frameworks:
- Genprex, Inc. 10Y Growth Potential
- Genprex, Inc. Scenario Analysis
- Genprex, Inc. Risks & Opportunities
- Genprex, Inc. Economic Moat
- Genprex, Inc. Business Model
- Genprex, Inc. Management
- Genprex, Inc. SWOT Analysis
- Genprex, Inc. Porter's 5 Forces
- Genprex, Inc. PESTLE Analysis
- Genprex, Inc. ESG Analysis